Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.94
    -0.42 (-0.50%)
     

  • GOLD FUTURES

    2,334.40
    -7.70 (-0.33%)
     

  • DOW

    38,481.08
    -22.61 (-0.06%)
     

  • Bitcoin GBP

    51,642.41
    -1,744.69 (-3.27%)
     

  • CMC Crypto 200

    1,390.28
    -33.82 (-2.38%)
     

  • NASDAQ Composite

    15,717.60
    +20.96 (+0.13%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Why Zogenix Stock Sank Today

Keith Speights, The Motley Fool
Updated

What happened

Shares of Zogenix (NASDAQ: ZGNX) closed Monday about 8.5% lower, a decline precipitated by the biotech's announcement that it plans to acquire privately held Modis Therapeutics for $250 million.

So what

Investing in biotech stocks, especially clinical-stage biotechs, is fraught with risk for a number of reasons. Zogenix's drop on Monday highlights the downsides of such companies making moves that their shareholders don't like. The sentiment on Wall Street appears skeptical when it comes to the decision to buy Modis, which has only one pipeline candidate -- MT1621, a drug that targets treatment of thymidine kinase 2 deficiency (TK2d), a rare genetic disease.

Businessman drawing big fish about to eat little fish
Businessman drawing big fish about to eat little fish

Image source: Getty Images.

ADVERTISEMENT

Modis recently completed a phase 2 clinical study evaluating MT1621 in treating TK2d; patients who took the drug achieved statistically significant improvement in survival probability and functional abilities. "Based on the compelling clinical data generated to date, we believe that MT1621 has the potential to significantly alter the course of the disease and improve outcomes in patients with TK2d," Zogenix CEO Stephen Farr said.

Given that Modis comes with a promising drug for a disease that has no approved therapies so far, why aren't investors happy about the acquisition? Probably because Zogenix isn't in the best financial position to be making deals. The company continues to lose money. It doesn't have an approved product on the market yet. And at the end of June, Zogenix's cash position stood at $463 million.

Buying Modis means that Zogenix will have significantly less cash on hand. Investors likely worry that the company could have to raise more capital by issuing new shares if the U.S. Food and Drug Administration (FDA) puts up any barriers to a relatively quick approval for MT1621, or if Zogenix's own drug candidate to treat Dravet syndrome, Fintepla, fails to win FDA approval.

Now what

There are several things for investors should watch with regards to Zogenix in the near term. The company plans to resubmit its filing for FDA approval of Fintepla in September. Fintepla is already under review by the European Medicines Agency (EMA). In addition, Zogenix plans to meet with both U.S. and European regulators on an accelerated approval pathway for MT1621, assuming the acquisition of Modis is finalized. The deal is expected to close next month.

More From The Motley Fool

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

This article was originally published on Fool.com